Therapeutic Area

Heart Failure

Therapeutic area intelligence for Heart Failure with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 0
Companies: 1

Companies

pharma companies with heart failure portfolios →

Assets

Cardiology →

Heart Failure →

HEARTFELT →

Recent signals(4)

ClinicalJune 20, 2026

HEARTFELT Study Evaluates Remote Monitoring Device for Heart Failure Management

The HEARTFELT study is assessing the safety and effectiveness of a remote patient monitoring device for heart failure patients.

ClinicalJune 20, 2026

Yale University Launches Digital Health Initiative for Heart Failure in Uganda

Yale University is implementing a digital-first care model for heart failure in Uganda, evaluating its effectiveness through a cluster-randomized trial.

ClinicalJune 18, 2026

Study on Optimizing CRT Lead Placement for Non-LBBB Patients Using Advanced Imaging Techniques

The RESYNC-PETCT study aims to improve CRT response in heart failure patients with non-LBBB or narrow LBBB patterns through advanced imaging guidance.

ClinicalJune 17, 2026

NORM-HF Study to Evaluate FIRE1 NORM™ System in Heart Failure Management

The NORM-HF study aims to show that the FIRE1 NORM™ System is superior to standard care in managing heart failure.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.